p53 is the most commonly mutated gene in human cancer. Although the loss of tumor suppressor functions for p53 in tumorigenesis is well characterized, gain-of-function p53 mutations observed in most cancers are not as widely appreciated. The human breast cancer cell line MDA-MB-231, which has high levels of a mutant p53, has high levels of phospholipase D (PLD) activity, which provides a survival signal in these cells when deprived of serum growth factors. We report here that the mutant p53 in MDA-MB-231 cells is stabilized by the elevated PLD activity in these cells. Surprisingly, the survival of MDA-MB-231 cells deprived of serum was dependent on the mutant p53. These data indicate that a mutant p53, stabilized by elevated PLD activity, can contribute to the suppression of apoptosis in a human breast cancer cell line and suggest a rationale for the selection of p53 mutations early in tumorigenesis to suppress apoptosis in an emerging tumor.
Introduction
Mutations in the p53 tumor suppressor gene are observed in greater than 50% of all human cancers (Hainaut and Hollstein, 2000) . However, unlike other tumor suppressor genes such as Rb and APC, over 85% of the mutations in the p53 gene are missense, rather than truncation or deletion mutants (Hinds et al., 1990; Hollstein et al., 1994; Hainaut and Hollstein, 2000) . The observation that other tumor suppressor genes are commonly deleted in tumors leading to loss-of-function phenotypes suggests that the low incidence of deletion mutants for p53 in human cancer reflects a positive selection for the missence mutations in p53. Moreover, mutant p53 in human cancer is commonly expressed at high levels and is more stable than wild-type p53 (Midgley and Lane 1997; Peng et al., 2001a, b; Asher et al., 2003) . These observations suggest that a positive selection for mutations to p53 that contribute to tumorigenesis. Initially, p53 was thought to be an oncogene because it was overexpressed in many cancers and p53 genes from transformed cells was able to act like a dominant oncogene in transformation assays (Eliyahu et al., 1984; Jenkins et al., 1984; Parada et al., 1984; Wolf et al., 1984) . One mechanism whereby mutant p53 can act like a dominant oncogene is through a 'dominant-negative' effect by interacting with and inactivating wild-type p53 (Blagosklonny, 2000) . However, wild-type/mutant p53 genotypes in human cancer are very rare (Blagosklonny, 2000) . p53 mutants have been shown to confer tumorigenic properties to cells lacking wild-type p53 (Dittmer et al., 1993; Hsiao et al., 1994; Lanyi et al., 1998; Scian et al., 2004) , indicating that the ability of p53 genes to contribute to cell transformation goes beyond dominant-negative effects. Moreover, tumor-derived p53 mutants have been shown to activate promoters not activated by wild-type p53 including those for the epidermal growth factor (EGF) receptor (Deb et al., 1994) , c-Myc (Frazier et al., 1998) and c-Fos (Preuss et al., 2000) , and others (van Oijen and Slootweg, 2000; Cadwell and Zambetti, 2001 ). There are 'hot spot' mutations at several sites in p53 (van Oijen and Slootweg, 2000) , indicating an apparent selection for mutants that confer an advantage to cells that have acquired these mutations.
In an emerging tumor, cells undergo the stress of nutrient, oxygen and growth factor deprivation before angiogenesis, which will ordinarily lead to apoptosis. Therefore, it is critical that tumor cells acquire the capability of suppressing default apoptotic signals to insure survival (Hanahan and Weinberg, 2000) . Phospholipase D (PLD) has emerged as a significant contributor to the survival of cancer cells (Foster and Xu, 2003; Foster, 2006) . MDA-MB-231 human breast cancer cells have high levels of PLD activity (Chen et al., 2003; Zhong et al., 2003) that generates a survival signal that suppresses apoptosis when these cells are subjected to the stress of serum withdrawal (Zhong et al., 2003; Chen et al., 2005) . We have investigated the impact of PLD on the mutant p53 in MDA-MB-231 cells. We report here that elevated PLD activity in MDA-MB-231 cells stabilizes the mutant p53 and that the p53 mutant in these cells is required for the survival of MDA-MB-231 breast cancer cells subjected to the stress of serum withdrawal.
Elevated expression of p53 in MDA-MB-231 cells is dependent upon PLD MDA-MB-231 cells have a mutant p53 (Olivier et al., 2002) , whereas MCF7 have wild-type p53 (Lu et al., 2001) . As shown in Figure 1a , MDA-MB-231 cells express very high levels of p53 relative to MCF7 cells. We previously reported that elevating PLD activity in MCF7 cells suppresses the stabilization of wild-type p53 (Hui et al., 2004) . As MDA-MB-231 cells have 10-fold greater PLD activity than MCF7 cells (Chen et al., 2003 (Chen et al., , 2005 , we examined the effect of suppressing PLD activity on p53 expression by introducing siRNA for PLD2 into MDA-MB-231 cells. PLD2 siRNA suppressed PLD activity ( Figure 1b ) and protein ( Figure 1c ) in MDA-MB-231 by close to 80%. Surprisingly, PLD2 siRNA reduced p53 levels in the MDA-MB-231 cells (Figure 1d ). Thus, while elevated PLD activity suppresses the expression of wild-type p53 (Hui et al., 2004) , PLD activity is apparently required for elevated expression of mutant p53 mutant MDA-MB-231 cells.
Elevated p53 in MDA-MB-231 cells is dependent upon MAP kinase, but not mTOR
We reported previously that signals generated by PLD lead to the activation of both MAP kinase (Shen et al., 2001; Hui et al., 2004) and mTOR (Chen et al., 2005) . PLD activity is required for endocytosis of the EGF receptor in response to EGF (Shen et al., 2001) , and endocytosis of the EGF receptor is required for activation of MAP kinase, but not for the activation of MEK, the kinase that phosphorylates MAP kinase (Kranenburg et al., 1999; Shen et al., 2001) . Consistent with these previous reports, the introduction of PLD2 siRNA into MDA-MB-231 cells suppressed the phosphorylation of MAP kinase, but not the phosphorylation of MEK (Figure 2a (Hui et al., 2004) . To control for loading, blots were re-probed with an antiactin antibody. (b) MDA-MB-231 cells (231 cells) were transfected with either control (Con) GAPDH or PLD2 siRNA (Ambion) and PLD activity was determined using the transphosphatidylation reaction as described previously (Hui et al., 2004) . The PLD activity in the cells treated with the PLD2 siRNA was normalized to the control, which was given a value of one. Error bars represent the standard deviation for duplicate samples. (c) Cells transfected with siRNA in B were also analysed for PLD2 protein levels by Western blot analysis. (d) MDA-MB-231 cells were transfected with either control (Con) GAPDH or PLD2 siRNA and the level of p53 was determined 72 h later as in (a). Experiments in (a, b, c and d) are representative of experiments repeated at least two times. MDA-MB-231 and MCF7 cells were obtained from the American Type Culture Collection and were maintained as described previously (Chen et al., 2005) . Transfection of siRNA was performed using LipofectAMINE 2000t reagent (Invitrogen, Chicago, IL, USA) according to the vendor's instructions. Monoclonal antibodies raised against p53 (pAb240 and pAb421), which recognize DNA-binding and C-terminal regions of p53 (Bargonetti et al., 1993) , were used for Western blot detection of p53. Antibodies against PLD2 and actin were from Upstate Biotechnology, Charlotesville, VA, USA and Santa Cruz Biotechnology, Santa Cruz, CA, USA, respectively. Figure 2b , the MEK inhibitor U0126 suppressed MAP kinase phosphorylation and p53 expression. These data indicate that the PLD-dependent increase in p53 in MDA-MB-231 cells is dependent on the MAP kinase pathway. The PLD metabolite phosphatidic acid has been reported to activate mTOR in a manner that is competitive with rapamycin (Fang et al., 2001; Chen et al., 2003) . We therefore examined the effect of rapamycin on p53 levels in MDA-MB-231 cells. As shown in Figure 2c , the level of p53 in MDA-MB-231 cells was insensitive to rapamycin at concentrations that inhibited the phosphorylation of the mTOR substrate ribosomal subunit S6 kinase. Thus, the PLD dependent expression of p53 is apparently dependent upon MAP kinase, but independent of mTOR.
Suppression of PLD or MAP kinase signaling increases the turnover of p53
The level of p53 is commonly regulated at the level of stabilization. Continuously expressed p53 is degraded by the proteasome after ubiquitination by the E3 ubiquitin ligase HDM2 (Moll and Petrenko, 2003) . To examine whether PLD signaling impacted on the stability of p53, we examined the level p53 protein in cells treated with cyclohexamide to inhibit new p53 protein. As shown in Figure 3a , the mutant p53 protein in MDA-MB-231 cells was relatively stable compared with the wild-type p53 in MCF7 cells over a 90 min time course of cyclohexamide treatment. However, if the cells were treated with U0126 (Figure 3b ) or PLD2 siRNA (Figure 3c ), the stability of p53 was reduced. Thus, the increased stability of p53 in MDA-MB-231 cells is enhanced by PLD and MAP kinase signaling.
We next examined the impact of suppressing PLD and MAP kinase on the association between p53 and HDM2 in MDA-MB-231 cells. As shown in Figure 3d , suppression of PLD activity with PLD2 siRNA led to an increased association between p53 and HDM2 as indicated by increased co-immunoprecipitation between p53 and HDM2. Similarly, suppression of MAP kinase activation with U0126 also increased the association between p53 and HDM2 (Figure 3e ). This observation is consistent with increased turnover of p53 observed when either PLD or MEK was suppressed. We reported previously that PLD activity increases MDM2 levels in rat fibroblasts (Hui et al., 2004) . We therefore examined the effect of PLD2 siRNA and U0126 on the level of HDM2 in MDA-MB-231 cells. Consistent with our previous study (Hui et al., 2004) , suppression of PLD activity (Figure 3f ) or MAP kinase activation (Figure 3g ) led to reduced HDM2 levels. Thus, in spite of reduced levels of HDM2 observed with inhibition of either PLD or MAP kinase signaling, there was still increased association between p53 and HDM2. These data argue that the increased turnover of p53 in response to suppression of PLD signaling is due to increased ubiquitination mediated by HDM2.
Survival signals generated by PLD are dependent upon mutant p53
Although there are p53 mutations that result in 'loss of function' to eliminate the tumor suppressing effects of p53 (Levine et al., 1991) , many mutations to p53 in human cancers are 'gain-of-function' mutations that can enhance tumorigenesis when introduced into other cells Figure 1 . Seventy-two hours later, lysates were immunoprecipited (IP) with an anti-p53 antibody (Cell Signaling Technology). The immunoprecipitates were then subjected to Western blot analysis (IB) with either HDM2 (Santa Cruz Biotechnology) or p53 (Bargonetti et al., 1993) antibodies as indicated. The strategy was then reversed and lysates were IP with HDM2 followed by Western blot with p53 and HDM2 antibodies as described previously (Hui et al., 2004) . (e) MDA-MB-231 cells were treated with either U0126 or DMSO control for 1 h. The cells were then lysed and the lysates were IP with an anti-p53 antibody and the immunoprecipitates were then subjected to Western blot analysis (IB) with either HDM2 or p53 antibodies as in (a). (f) MDA-MB-231 cells were transfected with either PLD2 or GAPDH control siRNA as in (a) and HDM2 levels were determined by Western blot. (g) MDA-MB-231 cells were treated with either U0126 or DMSO control for 1 h and HDM2 levels were determined as in (f). Experiments shown are representative of experiments repeated at least two times.
Mutant p53 and survival signals L Hui et al (Zambetti and Levine, 1993; Blandino et al., 1999; van Oijen and Slootweg, 2000; Cadwell and Zambetti, 2001) . As PLD provides a survival signal in MDA-MB-231 cells that suppresses apoptosis when cells are subjected to serum withdrawal (Zhong et al., 2003; Chen et al., 2005) , we investigated whether the PLD-dependent p53 expression in MDA-MB-231 is critical for the survival of these cells when subjected to serum withdrawal. We first examined the effect of suppressing PLD activity on cell viability and PARP cleavage in MDA-MB-231 cells subjected to serum withdrawal. As shown in Figure 4a , PLD2 siRNA reduced cell viability and increased PARP cleavage indicating that the loss in cell viability was due to apoptosis. Similarly, the MEK inhibitor U0126 also reduced cell viability and increased PARP cleavage in the MDA-MB-231 cells deprived of serum (Figure 4b ). We then examined the impact of p53 siRNA on the survival of MDA-MB-231 cells, and as shown in Figure 4c , the p53 siRNA strongly suppressed p53 expression and induced apoptosis in serum-starved MDA-MB-231 cells as indicated by loss of cell viability and increased PARP cleavage. These data indicate that the mutant p53 expressed in MDA-MB-231 cells is required for the survival of MDA-MB-231 cells deprived of serum and as the stabilization of p53 is dependent on PLD, the data indicate that the survival signals generated by PLD are at least partially dependent on p53.
In this report, we have demonstrated that PLD increases the half-life of the mutant p53 expressed in MDA-MB-231 cells and that the survival signals generated by PLD in these cells was dependent on the expression of this p53 mutant. Although survival signals generated by PLD are dependent on mTOR (Chen et al., 2005; Hui et al., 2005) , the effect of PLD on p53 expression in MDA-MB-231 cells was independent of mTOR, suggesting that activation of mTOR by PLD has additional effects for the survival signals generated by PLD. The effect of PLD on p53 expression in MDA-MB-231 cells was dependent on the MAP kinase pathway. This study reveals that the mutant p53 present in MDA-MB-231 cells, in collaboration with elevated PLD activity, is capable of providing a selective advantage to these cells by suppressing cell death. p53 mutants have been reported to act as dominantnegative mutants to suppress wild-type p53. However, there is no wild-type p53 in MDA-MB-231 cells (Katayose et al., 1995) , indicating that the impact mutant p53 upon the survival of MDA-MB-231 cells is not due to interfering with wild-type p53. Mutant p53 proteins have also been reported to suppress the proapoptotic effects of the p53 family member p73 (Strano and Blandino, 2003; Irwin, 2004) . Of interest in this matter is that mutant p53 proteins from SK-BR3 and T47D breast cancer cell lines interact functionally with p73 . We have found that suppressing the expression of the mutant p53 in these cells does not increase survival when these cells are deprived of serum (our unpublished results), suggesting that the effect of the mutant p53 in MDA-MB-231 cells is not due to inactivating p73. Thus, it is not likely that the effect of the mutant p53 in MDA-MB-231 cells reported here involves interaction with other p53 family members. Survival signals generated by PLD is dependent upon mutant p53. (a) MDA-MB-231 cells were plated in Dulbecco's modified Eagle's medium (DMEM) with 10% serum for 24 h. The cells were then transfected with either control GAPDH or PLD2 siRNA. Twenty-four hours later, the cells were shifted to fresh media containing 0% serum for 48 h, at which time the percentage of non-viable cells was determined by trypan blue exclusion as described previously (Hui et al., 2004 (Hui et al., , 2005 . At this time, cells were also examined for the level of cleaved PARP (Cl PARP) and PLD2 protein using Western blot analysis as described previously (Hui et al., 2004 (Hui et al., , 2005 . Blots were stripped and reprobed with an antibody to actin to control for loading. The ability of PLD to increase the level of p53 was surprising, in that our previous study indicated that elevated PLD activity suppresses DNA damage-induced increases in wild-type p53 (Hui et al., 2004) . The mechanism for suppression of p53 by PLD was apparently due to increased expression of HDM2. Suppression of PLD activity led to a reduced level of HDM2 in the MDA-MB-231 cells. However, in spite of the reduced level of HDM2 observed with PLD2 siRNA, there was increased association between p53 and HDM2, indicating that elevated PLD activity in MDA-MB-231 was suppressing the interaction between p53 and HDM2. Suppression of the p53-HDM2 interaction was dependent upon MAP kinase, suggesting that phosphorylation may play a role. However, MAP kinase has not been shown to phosphorylate p53 directly. Thus, at this point it is not clear how the p53 -HDM2 interaction is disrupted with elevated PLD activity.
p53 mutations are by far the most common in human cancer, with some estimates indicating that as many as 70% of human cancers have mutations in the p53 gene. Although knocking out the tumor suppressing effects of p53 is critical for allowing passage through cell cycle checkpoints, the ability of point mutations in the p53 gene to produce p53 proteins with dominant gain-offunction oncogenic properties makes p53 a double edged sword. As indicated here, an early point mutation in p53 could contribute to the survival of an emerging tumor before vascularization where stressful conditions promote cell death. Loss of heterozygosity for the p53 gene, which generally occurs late in tumorigenesis (Kinzler and Vogelstein, 1996) , would further abrogate any remaining tumor suppressing effects of wild-type p53. Data provided here demonstrate that in the human breast cancer cell line MDA-MB-231, p53 is required for survival under conditions of serum withdrawalconditions similar to that in an emerging tumor before vascularization. A critical problem for tumorigenesis in cells with two wild-type alleles is obtaining mutations to both genes in the same cells. The probability of generating mutations on both alleles is quite remote unless there is a selection for the first mutation. In the case of p53, the mutation in MDA-MB-231 cells is able to contribute to survival signals that are critical early in tumorigenesis to suppress default apoptotic programs. Once a dominant p53 mutation is selected for, progression to loss of heterozygosity would be relatively common and generate a complete loss-of-function for the tumor suppressing gatekeeper function of p53. Elevated PLD activity could enhance the effectiveness of p53 mutations by increasing the stability of the mutant p53 relative to the wild-type p53.
